Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis

Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis

Abstract Background Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically alter the stool microbiota. As the ant...

Full description

Bibliographic Details
Main Authors: Kazuhiko Ikeuchi, Takeya Tsutsumi, Aya Ishizaka, Taketoshi Mizutani, Ayako Sedohara, Michiko Koga, Satoru Tamaoki, Hiroshi Yotsuyanagi
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Gut Pathogens
Subjects:
Microbiome
Liver fibrosis
Small intestine
Hepatic encephalopathy
Lactobacillaceae
Firmicutes
Online Access:https://doi.org/10.1186/s13099-023-00541-4

Internet

https://doi.org/10.1186/s13099-023-00541-4

Similar Items